Stephen Holgate (physician)

For the footballer, see Stephen Holgate.British physician (born 1947)

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)

A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Misplaced Pages's content policies, particularly neutral point of view. Please discuss further on the talk page. (January 2023) (Learn how and when to remove this message)

This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (January 2023) (Learn how and when to remove this message)

This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (April 2023) (Learn how and when to remove this message)

(Learn how and when to remove this message)

SirStephen HolgateCBE FRCP FRCPath MAE FMedSci
Born	Stephen Townley Holgate (1947-05-02) 2 May 1947 (age 77) Heywood, Lancashire, England
Occupation	Physician
Spouse	Elizabeth Holgate
Children	4

Sir Stephen Townley Holgate (born 2 May 1947) is a British physician who specializes in immunopharmacology, respiratory medicine and allergies, and asthma and air pollution, based at the University of Southampton and University Hospital Southampton NHS Foundation Trust, UK.

Education

This section of a biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libelous.
Find sources: "Stephen Holgate" physician – news · newspapers · books · scholar · JSTOR (January 2023) (Learn how and when to remove this message)

Holgate was educated at The King's School in Macclesfield until 1965, when he joined Charing Cross Hospital Medical School, London (now incorporated into Imperial College London) where he received a BSc and MB BS. After completing postgraduate medical training in London at the National Hospital for Nervous Diseases and the Royal Brompton Hospital, he moved to Salisbury and Southampton where he completed his specialist higher medical training in general and respiratory medicine.

While a Clinical Lecturer at the University of Southampton, he researched the link between asthma death and over-use of beta-adrenergic bronchodilator inhalers. In 1978, Holgate received a Doctor of Medicine (MD) degree from the University of London.

In 1980, Holgate completed a two year post doctoral fellowship with K. Frank Austen at the Robert Brigham Hospital and Harvard University, Boston provided by the Dorothy Temple Cross MRC endowment and the Wellcome Trust.

Career and research

In 1980, Holgate began work at the University of Southampton researching the causes of human asthma and its treatment. After establishing the role that mast cells and other effector cells play in triggering the acute allergic inflammatory response in asthma, he examined the mechanisms of asthma chronicity and variability.

In 2002, Holgate collaborated with Donna Davies and Genome Therapeutics Corporation in Waltham, Mass, USA to identify the first novel asthma susceptibility gene of ADAM33 that encodes a metalloprotease linked to airway hyperresponsiveness and remodelling. This originated from the theory that in severe asthma, the airways behaved like a chronic wound with impaired epithelial repair and underlying tissue remodelling involving the deposition of new matrix, mucous metaplasia and proliferation of smooth muscle.

Holgate and his research group demonstrated the causal link between exacerbations in the autumn and winter months and respiratory virus infections. This led to the subsequent discovery that epithelial cells from those with moderate-severe asthma were deficient in their ability to generate an innate interferon beta response when infected by human rhinoviruses.

In 2003 Holgate, Donna Davies and Ratko Djukanovic [Wikidata] used this patented information to create the University spin-off company Synairgen to explore the potential therapeutic benefits of inhaled interferon beta in attenuating virus-induced exacerbations of asthma and COPD. Synairgen completed a Phase II placebo-controlled trial to treat COVID-19.

Awards and honours

Holgate was appointed Commander of the Order of the British Empire (CBE) in 2011 and was knighted in 2020 for services to medical research.

References

"Professor Stephen T. Holgate - King Faisal International Prize". Kfip.org. Retrieved 22 October 2017.
"Professor Stephen Holgate". southampton.ac.uk. University of Southampton. Retrieved 22 October 2017.
"Stephen Townley HOLGATE". London: Companies House.
Holgate, Stephen Townley (1978). Beta-Adrenergic Resistance - The development and Mechanisms in normal man. london.ac.uk (MD thesis). University of London. OCLC 1006020949. EThOS uk.bl.ethos.459448.
"Professor Stephen Holgate CBE - AAIR Charity". Aaircharity.org. Retrieved 22 October 2017.
"Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus". scholar.google.com. Retrieved 20 August 2024.
Holgate, Stephen; Agusti, Alvar; Strieter, Robert M.; Anderson, Gary P.; Fogel, Robert; Bel, Elisabeth; Martin, Thomas R.; Reiss, Theodore F. (2015). "Drug development for airway diseases: looking forward". Nature Reviews Drug Discovery. 14 (6): 367–368. doi:10.1038/nrd4645. ISSN 1474-1776. PMID 26000726. S2CID 8539798.
"Southampton respiratory drug discovery spin-out seeks partnership". sciencebusiness.net. Retrieved 25 July 2020.
Neate, Rupert (24 July 2020). "'Major' breakthrough in Covid-19 drug makes UK professors millionaires". The Guardian. London. ISSN 0261-3077. Retrieved 25 July 2020.
"No. 63135". The London Gazette (Supplement). 10 October 2020. p. B2.

Categories: